Tau Propagation Blockers For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tau propagation blockers represent an emerging therapeutic strategy targeting the spreading of pathological tau protein through neural circuits. These agents aim to prevent the cell-to-cell transmission of tau aggregates that characterizes Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and other tauopathies.
- Release: Pathological tau is released from donor neurons
- Uptake: Tau seeds are taken up by recipient neurons via endocytosis
- Seeding: Exogenous tau seeds induce aggregation of endogenous tau
- Transmission: This process repeats, spreading pathology throughout connected brain regions
- Extracellular vesicles: May facilitate tau spread
- Muscle networks: Cell surface tau binding and internalization
- Lysosomal dysfunction: Affects intracellular processing of tau seeds
¶ Antibody-Based Blockers
| Agent |
Target |
Development Stage |
| Gosutromab |
Tau aggregates |
Phase II (Alzheimer's) |
| Semorinemab |
Tau |
Phase II (AD) |
| Tilavonemab |
Tau |
Phase II (PSP) |
| Compound |
Mechanism |
Development Stage |
| Methylene blue derivatives |
Tau aggregation |
Phase III |
| Curcumin analogs |
Tau aggregation |
Preclinical |
| Nicotinamide |
SIRT1 activation, tau deacetylation |
Phase II |
- Antisense oligonucleotides: Target tau mRNA
- miRNA-based: Modulate tau expression
- CRISPR: Future allele-specific editing
- Tau spreading correlates with cognitive decline
- Targeting early propagation may preserve cognition
- Combination with anti-Aβ therapy may be synergistic
- Pure tauopathy model
- May respond well to propagation blockers
- Several trials ongoing
- 4R tau accumulation
- Propagation mechanisms similar to PSP
- Targeting both pathological forms important
- Large molecules require intrathecal or intravenous delivery
- Engineering for BBB penetration ongoing
- Focused ultrasound for temporary opening
- Measuring tau propagation in vivo is challenging
- PET ligands for tau aggregates
- CSF tau species as biomarkers
¶ Antibody-Based
- Amyloid-related imaging abnormalities (ARIA)
- Infusion reactions
- Immunogenicity
- Generally well-tolerated
- Gastrointestinal effects
- Potential off-target effects
- Antibody-based tau reduction + propagation blocking
- Sequential or simultaneous approaches
- Anti-Aβ + anti-tau combination
- Synergistic effects expected
- Agents targeting both tau aggregation and propagation
- Combined antibody-small molecule therapy
- Genetic risk factors for tau vulnerability
- Biomarker-driven treatment selection
The study of Tau Propagation Blockers For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Xia Y, et al. Tau propagation: models, mechanisms, and implications. Nat Rev Neurosci. 2023.
- Guo JL, et al. Tau prions. Annu Rev Neurosci. 2022.
- Villemagne VL, et al. Tau imaging: early detection and spread. J Neurol Neurosurg Psychiatry. 2023.
Monoclonal antibodies targeting tau include:
- Lecanemab: Binds protofibrils, approved for early Alzheimer's
- Donanemab: Targets pyroglutamated tau
- Semorinemab: Targets mid-domain tau
Small molecules that inhibit tau aggregation include methylene blue derivatives, anthraquinones, and phenylthiazoles. Many have shown efficacy in preclinical models.
AAV-vector delivered anti-tau RNAi and CRISPR-based gene editing are being developed to provide long-term tau reduction in the brain.